lenacapavir
Trial Shows Lenacapavir + bNAbs As Possible HIV Treatment
New longer-acting treatment options for HIV may be on the horizon.
JULY 31, 2025
Key Takeaways for PrEP, HIV Treatment and Other Infectious Diseases
CROI 2025 highlighted promising therapeutic modalities for HIV treatment and prevention.
JULY 9, 2025
FDA Approves Yeztugo for HIV PrEP Lasting 6 Months
The FDA approved lenacapavir, an injectable HIV-1 capsid inhibitor, to be used as PrEP to reduce the risk of ...
JUNE 18, 2025
Twice-Yearly Lenacapavir Sets a New PrEP Standard
The results of an interim analysis from a second pivotal phase 3 clinical trial investigating the use of ...
OCTOBER 27, 2024
Twice-Yearly Lenacapavir for PrEP Reduced HIV Infections by 96%
The independent Data Monitoring Committee recommended that Gilead stop the blinded phase of the trial and offer ...
SEPTEMBER 13, 2024
Bictegravir and Lenacapavir an Effective ART Switch for People With HIV
A novel combination of bictegravir and lenacapavir appears highly effective in maintaining viral suppression over ...
JULY 29, 2024
Oral Bridging of Lenacapavir Maintains Viral Suppression Among HIV Patients
Oral bridging of lenacapavir enabled patients to maintain viral suppression of their HIV after missed doses of ...
JULY 26, 2023
Investigational Combo Lenacapavir + bNAbs Would Push HIV Treatment to Twice Yearly
The investigational combination of lenacapavir with two broadly neutralizing antibodies would make twice-yearly HIV ...
FEBRUARY 24, 2023
FDA Approves Sunlenca for Adults With Resistant HIV
The FDA approved lenacapavir, a first-in-class, long-acting HIV capsid inhibitor, which is injected twice ...
DECEMBER 22, 2022
No Approval for Lenacapavir Due to Vial Compatibility Issues
The FDA issued a complete response letter for the New Drug Application for lenacapavir, an investigational, ...
MARCH 3, 2022
